Jump to the top of the page

Investment Banking

The Quarterly Rx: Q3 2022 U.S. Biopharma Recap

While biopharma markets stabilized in Q3 2022—providing issuers with the most constructive financing environment we have seen year-to-date—macroeconomic issues remain the key headline risk for the near term. Key biopharma indices bounced off multiyear lows, driven by encouraging signs of M&A, meaningful positive clinical news, and broad sector short covering. William Blair's Biopharma team shares perspectives in “The Quarterly Rx: Q3 2022 U.S. Biopharma Recap.

Complete the form below to download your copy of the report.

Delivered to Your Inbox

Stay up-to-date with the latest William Blair news and insights

Subscribe to News Alerts

More News and Insights

  • TeraWulf Inc.: Initiation of Research Coverage

    William Blair initiated research coverage of TeraWulf Inc. (WULF $15.97), a developer and operator of large-scale digital infrastructure that converts power-rich sites into high-performance computing and AI data center campuses.

    Read more

  • Economics Weekly: The Path of Least Resistance for Yields Is Still Higher

    In this Economics Weekly, Richard de Chazal discusses what factors are driving yields higher and the historical response from policymakers.

    Read more

  • Becoming a Parent: 10 Steps to Financially Prepare for a Growing Family

    If you or a loved one are preparing to welcome a child, here are 10 financial steps to consider.

    Read more
See more insights

Are you sure you want to leave?

Information contained on the internet is not subject to William Blair & Company's control or review, and may not be accurate.

For disclosure information, please visit www.williamblair.com/disclosures